Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now
story of the week
Published in Oncology and
1 other channel

Journal Scan / Research · August 17, 2017

Health-Related Quality of Life With Immediate vs Delayed Androgen-Deprivation Therapy in Patients With Asymptomatic, Non-Curable Prostate Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Thomas Guzzo MD, MPH

The Lancet Oncology
Health-Related Quality of Life for Immediate Versus Delayed Androgen-Deprivation Therapy in Patients With Asymptomatic, Non-Curable Prostate Cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): A Randomised, Multicentre, Non-Blinded, Phase 3 Trial
Lancet Oncol 2017 Jul 28;[EPub Ahead of Print], GM Duchesne, HH Woo, M King, SJ Bowe, MR Stockler, A Ames, C D'Este, M Frydenberg, A Loblaw, S Malone, J Millar, KH Tai, S Turner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated